Currently, endocrine therapies such as selective ER modulators (SERMs) and aromatase inhibitors (AIs) remain the standard of care adjuvant systemic therapy for primary HR+ breast cancer (Table 1). This evidence concerns the gene ESR1 and breast cancer.